Paratek Pharmaceuticals Inc., of Boston, said it planned to offer $60 million of its common stock in an underwritten public offering to support ongoing and planned trials of omadacycline, an oral and intravenous once-daily antibiotic with activity against gram-positive, gram-negative, atypical and anaerobic bacteria, as well as to advance its pipeline and preclinical candidates.